Amarin Corp Plcuk (AMRN) Payables (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Payables of $48.2 million for Q1 2026, up 5.46% year-over-year from $45.7 million in Q1 2025, and up 6.17% quarter-over-quarter from $45.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Payables (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Payables data on file, last reported at $48.2 million in Q1 2026.
- Payables for Q1 2026 came in at $48.2 million, up 5.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $48.2 million (up 5.46% YoY), and the FY2025 annual result was $45.4 million, up 12.36% from the prior year.
- Payables grew to $48.2 million in Q1 2026 per AMRN's latest filing, from $45.4 million in the prior quarter.
- Over five years, Payables peaked at $116.3 million in Q2 2022 and troughed at $36.7 million in Q3 2025.
- A 5-year average of $59.3 million and a median of $53.4 million in 2023 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables climbed 28.64% in 2022, then slumped 53.31% in 2023.
- A 5-year view of Payables shows it stood at $64.6 million in 2022, then fell by 18.33% to $52.8 million in 2023, then declined by 23.49% to $40.4 million in 2024, then grew by 12.36% to $45.4 million in 2025, then climbed by 6.17% to $48.2 million in 2026.
- Business Quant data shows AMRN's Payables at $48.2 million in Q1 2026, $45.4 million in Q4 2025, and $36.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -26.13 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.03 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 27.92 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 33.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 6.01 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.94 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 645.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 4.51 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 4.23 Bn |
| 10 | Amarin Corp Plcuk | 6.77 Bn | 6.59 Bn | 17.77 Mn | 48.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.15 Mn |
| Dec 31, 2025 | 45.36 Mn |
| Sep 30, 2025 | 36.71 Mn |
| Jun 30, 2025 | 44.71 Mn |
| Mar 31, 2025 | 45.66 Mn |
| Dec 31, 2024 | 40.37 Mn |
| Sep 30, 2024 | 40.51 Mn |
| Jun 30, 2024 | 54.38 Mn |
| Mar 31, 2024 | 67.60 Mn |
| Dec 31, 2023 | 52.76 Mn |
| Sep 30, 2023 | 53.36 Mn |
| Jun 30, 2023 | 54.31 Mn |
| Mar 31, 2023 | 58.78 Mn |
| Dec 31, 2022 | 64.60 Mn |
| Sep 30, 2022 | 93.16 Mn |
| Jun 30, 2022 | 116.31 Mn |
| Mar 31, 2022 | 90.75 Mn |
| Dec 31, 2021 | 114.92 Mn |
| Sep 30, 2021 | 72.42 Mn |
| Jun 30, 2021 | 141.25 Mn |